Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting

被引:22
作者
Del Vecchio, GC
Crollo, E
Schettini, F
Schettini, F
Fischer, R
De Mattia, D
机构
[1] Univ Bari, Policlin, Dipartimento Biomed Eta Evolut, I-70124 Bari, Italy
[2] Univ Krankenhaus Eppendorf, Inst Med Biochem Mol Biol, Hamburg, Germany
关键词
deferiprone; oral chelator; thalassaemia;
D O I
10.1159/000039759
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The effectiveness of deferiprone (L1) and the influence of other factors were determined in a clinical setting. Patients of Southern Italian origin, affected by beta -thalassaemia major (n = 13: 7 M, 6 F), aged 10-28 years (median 18 years), were treated with L1 within a 'Controlled Programme' of the Italian Ministry of Health, Desferrioxamine could not be administered in these patients because of anaphylactic reactions or other serious side effects, L1 was considered to be effective when the liver iron concentration was reduced or stable as measured by biomagnetic liver susceptometry, L1 proved to be effective in 3 out the 9 evaluable patients, A high pre-L1 iron overload was the main clinical factor influencing L1 effectiveness.
引用
收藏
页码:99 / 102
页数:4
相关论文
共 24 条
[1]   Meta-analytic review of the clinical effectiveness of oral deferiprone (L1) [J].
Addis, A ;
Loebstein, R ;
Koren, G ;
Einarson, TR .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (01) :1-6
[2]   LONG-TERM ASSESSMENT OF EFFICACY AND SAFETY OF L1, AN ORAL IRON CHELATOR, IN TRANSFUSION DEPENDENT THALASSEMIA - INDIAN TRIAL [J].
AGARWAL, MB ;
GUPTE, SS ;
VISWANATHAN, C ;
VASANDANI, D ;
RAMANATHAN, J ;
DESAI, N ;
PUNIYANI, RR ;
CHHABLANI, AT .
BRITISH JOURNAL OF HAEMATOLOGY, 1992, 82 (02) :460-466
[3]  
ALREFAIE FN, 1992, BLOOD, V80, P593
[4]   TOXICITY OF ORAL IRON CHELATOR L1 [J].
BERDOUKAS, V ;
BENTLEY, P ;
FROST, H ;
SCHNEBLI, HP .
LANCET, 1993, 341 (8852) :1088-1088
[5]  
BORGNAPIGNATTI C, 1991, HAEMATOLOGICA, V76, P409
[6]   MAGNETIC-SUSCEPTIBILITY MEASUREMENT OF HUMAN IRON STORES [J].
BRITTENHAM, GM ;
FARRELL, DE ;
HARRIS, JW ;
FELDMAN, ES ;
DANISH, EH ;
MUIR, WA ;
TRIPP, JH ;
BELLON, EM .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (27) :1671-1675
[7]  
COLLINS AF, 1994, BLOOD, V83, P2329
[8]   RETRACTED: An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major (Retracted article. See vol. 41, pg. 256, 2019) [J].
Diav-Citrin, O ;
Atanackovic, G ;
Koren, G .
THERAPEUTIC DRUG MONITORING, 1999, 21 (01) :74-81
[9]  
Fischer R, 1999, AM J HEMATOL, V60, P289, DOI 10.1002/(SICI)1096-8652(199904)60:4<289::AID-AJH7>3.0.CO
[10]  
2-W